Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Microsatellite Instability 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × avelumab × Clear all
NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

EMD Serono

Phase 3 Completed
371 enrolled 18 charts
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡